Evaluation of Risk for Late Language Emergence After in Utero Antiretroviral Drug Exposure in HIV-exposed Uninfected Infants

Pediatric Infectious Disease Journal

Volumn 32, Issue 10, 2013, Pages e406-e413

  Rice, Mabel L ^a   Zeldow, Bret ^a   Siberry, George K ^a   Purswani, Murli ^a   Malee, Kathleen ^a   Hoffman, Howard J ^a   Frederick, Toni ^a   Buchanan, Ashley ^a   Sirois, Patricia A ^a   Allison, Susannah M ^a   Williams, Paige L ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Antiretroviral; Cohort study; HIV exposed infants; Language delay; Pregnancy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; SAQUINAVIR; STAVUDINE; TENOFOVIR; ZIDOVUDINE;

CAREGIVER; CHILD; COHORT ANALYSIS; CONFERENCE PAPER; EVALUATION STUDY; FEMALE; HIGH RISK INFANT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LANGUAGE DELAY; MAJOR CLINICAL STUDY; MALE; PERINATAL DRUG EXPOSURE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; VIRUS TRANSMISSION;

ANTI-RETROVIRAL AGENTS; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HUMANS; INFANT; LANGUAGE DEVELOPMENT DISORDERS; MALE; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL EXPOSURE DELAYED EFFECTS; PROSPECTIVE STUDIES;

EID: 84891776147     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31829b80ee     Document Type: Article

References (27)

1. Zubrick SR, Taylor CL, Rice ML, et al. Late language emergence at 24 months: an epidemiological study of prevalence, predictors, and covariates. J Speech Lang Hear Res. 2007;50:1562-1592
2. Reilly S, Bavin EL, Bretherton L, et al. The Early Language in Victoria Study (ELVS): A prospective, longitudinal study of communication skills and expressive vocabulary development at 8, 12 and 24 months. Int J Speech Lang Pathol. 2009;11:344-357
3. Feldman HM, Dollaghan CA, Campbell TF, et al. Measurement properties of the MacArthur communicative development inventories at ages one and two years. Child Dev. 2000;71:310-322
4. Bloomfield FH. Epigenetic modifications may play a role in the developmental consequences of early life events. J Neurodev Disord. 2011;3:348-355
5. Quigley MA, Poulsen G, Boyle E, et al. Early term and late preterm birth are associated with poorer school performance at age 5 years: a cohort study. Arch Dis Child Fetal Neonatal Ed. 2012;97:F167-F173
6. Mattson SN, Riley EP, Gramling L, et al. Neuropsychological comparison of alcohol-exposed children with or without physical features of fetal alcohol syndrome. Neuropsychology. 1998;12:146-153
7. Taylor AN, Chiappelli F, Tritt SH, et al.Hodgson DM, Coe DL Maternal alcohol consumption and neuroendocrine-immune interactions in the offspring. In: Perinatal Programming: Early Life Determinants of Adult Health and Disease. 2005 London, UK Taylor & Francis
8. Rice ML, Buchanan AL, Siberry GK, et al. Language impairment in children perinatally infected with HIV compared to children who were HIV-exposed and uninfected. J Dev Behav Pediatr. 2012;33:112-123
9. Griner R, Williams PL, Read JS, et al.Pediatric HIV/AIDS Cohort Study. in utero and postnatal exposure to antiretrovirals among HIV-exposed but uninfected children in the United States. AIDS Patient Care STDS. 2011;25:385-394
10. Le Doaré K, Bland R, Newell ML. Neurodevelopment in children born to HIV-infected mothers by infection and treatment status. Pediatrics. 2012;130:e1326-e1344
11. Sirois PA, Huo Y, Williams PL, et al. Safety of perinatal exposure to antiretroviral mediations: Developmental outcomes in infants. Pediatr Infect Dis J. 2013;32:648-655
12. Bayley N Bayley Scales of Infant and Toddler Development. 20063rd ed San Antonio, TX Harcourt Assessment
13. Williams PL, Seage GR 3rd, Van Dyke RB, et al.Pediatric HIV/AIDS Cohort Study. A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothers. Am J Epidemiol. 2012;175:950-961
14. Fenson L, Marchman VA, Thal DJ, et al. MacArthur-Bates Communicative Development Inventories. 2007 Baltimore, MD Paul H. Brookes
15. Tassiopoulos K, Read JS, Brogly S, et al. Substance use in HIV-Infected women during pregnancy: self-report versus meconium analysis. AIDS Behav. 2010;14:1269-1278
16. van Noort-van der Spek IL, Franken MC, Weisglas-Kuperus N. Language functions in preterm-born children: a systematic review and meta-analysis. Pediatrics. 2012;129:745-754
17. Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis. 2012;54:1348-1360
18. Powis KM, Kitch D, Ogwu A, et al. Increased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancy. J Infect Dis. 2011;204:506-514
19. Wilcox JJ, Weinberg CF, Basso O. On the pitfalls of adjusting for gestational age at birth. Am J Epidemiol. 2011;174:1062-1068
20. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. 2011 Rockville, MD Public Health Service Task Force:85-87
21. Mandelbrot L, Mazy F, Floch-Tudal C, et al. Atazanavir in pregnancy: impact on neonatal hyperbilirubinemia. Eur J Obstet Gynecol Reprod Biol. 2011;157:18-21
22. Conradie F, Zorrilla C, Josipovic D, et al. Safety and exposure of once-daily ritonavir-boosted atazanavir in HIV-infected pregnant women. HIV Med. 2011;12:570-579
23. Newman TB, Liljestrand P, Jeremy RJ, et al.Jaundice and Infant Feeding Study Team. Outcomes among newborns with total serum bilirubin levels of 25舁mg per deciliter or more. N Engl J Med. 2006;354:1889-1900
24. Ip S, Chung M, Kulig J, et al.American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. An evidence-based review of important issues concerning neonatal hyperbilirubinemia. Pediatrics. 2004;114:e130-e153
25. Jangaard KA, Fell DB, Dodds L, et al. Outcomes in a population of healthy term and near-term infants with serum bilirubin levels of >or=325 micromol/L (>or=19舁mg/dL) who were born in Nova Scotia, Canada, between 1994 and 2000. Pediatrics. 2008;122:119-124
26. Hankø E, Hansen TW, Almaas R, et al. Bilirubin induces apoptosis and necrosis in human NT2-N neurons. Pediatr Res. 2005;57:179-184
27. Rodrigues CM, Solá S, Brites D. Bilirubin induces apoptosis via the mitochondrial pathway in developing rat brain neurons. Hepatology. 2002;35:1186-1195